Bhattacharya Anindya, Schenck Kathryn W, Cohen Marlene L
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.
Am J Physiol Heart Circ Physiol. 2003 Feb;284(2):H719-26. doi: 10.1152/ajpheart.00345.2002. Epub 2002 Nov 7.
The modulation of serotonin (5-HT(1B/1D)) receptor-induced vascular contractility by histamine and U-46619 was compared in the rabbit basilar artery and saphenous vein. In the saphenous vein, histamine (5 x 10(-7) M) significantly increased the potency (from pEC(50) of 6.0 to 6.8) and efficacy (from 52.3% to 88.2%) of sumatriptan. Likewise, U-46619 (5 x 10(-9) M) also increased the potency (from pEC(50) of 5.9 to 6.6) and efficacy (from 51.8% to 92.1%) of sumatriptan in the saphenous vein. In contrast, equieffective concentrations of histamine (10(-7) M) and U-46619 (3 x 10(-9) M) failed to amplify contraction to sumatriptan in the basilar artery. Contraction to sumatriptan was inhibited by nitrendipine (10(-7) M) in the basilar artery but not in the saphenous vein, suggesting that different contractile signaling mechanisms are operating in these tissues. Furthermore, U-46619- and thrombin-induced contractility in the basilar artery were also not amplified by histamine, suggesting that lack of amplification of contraction in the basilar artery was not restricted to sumatriptan but was rather a characteristic of this cerebral vessel. These data suggest that in the in vivo plasma milieu sumatriptan will more markedly contract the peripheral saphenous vein than the basilar artery, a cerebral blood vessel.
在兔基底动脉和隐静脉中比较了组胺和U - 46619对5 - 羟色胺(5 - HT(1B/1D))受体诱导的血管收缩的调节作用。在隐静脉中,组胺(5×10⁻⁷ M)显著提高了舒马曲坦的效价(从pEC₅₀为6.0提高到6.8)和效能(从52.3%提高到88.2%)。同样,U - 46619(5×10⁻⁹ M)也提高了隐静脉中舒马曲坦的效价(从pEC₅₀为5.9提高到6.6)和效能(从51.8%提高到92.1%)。相比之下,等效应浓度的组胺(10⁻⁷ M)和U - 46619(3×10⁻⁹ M)未能增强基底动脉对舒马曲坦的收缩反应。在基底动脉中,尼群地平(10⁻⁷ M)可抑制对舒马曲坦的收缩反应,但在隐静脉中则无此作用,这表明这些组织中存在不同的收缩信号传导机制。此外,组胺也未增强U - 46619和凝血酶诱导的基底动脉收缩,这表明基底动脉收缩反应缺乏增强并非仅限于舒马曲坦,而是该脑血管的一个特征。这些数据表明,在体内血浆环境中,舒马曲坦对周围隐静脉的收缩作用比对脑血管基底动脉更为明显。